Charcoal: Clinical Trials

28 trials of Charcoal, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed. 28 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 128Completed 28

Follow Charcoal: new trials by email Literature Review of Charcoal trials Research Report on Charcoal

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)
budesonide, Activated Charcoal - Healthy
Phase 1CompletedUnither Pharmaceuticals, France242024-08-132024-11-08
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal) - Chronic Obstructive Pulmonary Disease
Phase 1CompletedAstraZeneca1082022-07-292025-08-28
A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants
Mavacamten, Activated Charcoal with Sorbitol - Healthy Participants
Phase 1CompletedBristol-Myers Squibb452022-04-152022-11-08
Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product
Indacaterol/glycopyrronium - Healthy Volunteers
Phase 1CompletedOrion Corporation, Orion Pharma242022-02-282022-07-13
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
Rivaroxaban, Activated charcoal - Healthy
Phase 1CompletedCentre Hospitalier Universitaire de Saint Etienne122022-01-032022-12-05
Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler
Indacaterol maleate and glycopyrronium bromide, Ultibro Breezhaler with oral charcoal - Healthy Volunteers
Phase 1CompletedOrion Corporation, Orion Pharma342021-05-072021-09-28
Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler®
Tiotropium Bromide Monohydrate, Tiotropium Easyhaler with oral activated charcoal - Healthy Volunteers
Phase 1CompletedOrion Corporation, Orion Pharma432021-04-262021-10-25
To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.
Combined oral contraceptives (COC), Moxifloxacin 400mg, Cenerimod 0.5 mg - Healthy Subjects
Phase 1CompletedViatris Innovation GmbH972020-01-312025-09-22
Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects
Sotagliflozin (SAR439954), 14C-microtracer, Charcoal - Type 2 Diabetes Mellitus, Healthy Subjects
Phase 1CompletedSanofi62019-01-142022-04-25
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus
Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus - Asthma
Phase 1CompletedOrion Corporation, Orion Pharma642016-07-012017-03-03
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
GSK2269557 ELLIPTA DPI, Placebo ELLIPTA DPI, Activated charcoal - Pulmonary Disease, Chronic Obstructive
Phase 1CompletedGlaxoSmithKline222016-03-142017-04-26
Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects
rivaroxaban, rivaroxaban and activated charcoal - Healthy
Phase 1CompletedCentre Hospitalier Universitaire de Saint Etienne122016-01-012016-05-25
Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler
Budesonide/formoterol, Charcoal, Symbicort Turbuhaler - Asthma
Phase 1CompletedOrion Corporation, Orion Pharma202016-01-012017-03-08
Clinical Study to Evaluate Z7200 Pharmacokinetics Profile
Z7200 without oral activated charcoal, Symbicort Turbohaler without oral activated charcoal, Z7200 with oral activated charcoal - Asthma
Phase 1CompletedZambon SpA912016-01-012022-02-23
Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
SUN-101 via eFlow nebulizer, SUN-101 via eFlow nebulizer with activated charcoal, Seebri® Breezhaler® - COPD
Phase 1CompletedSunovion Respiratory Development Inc.302015-10-012018-10-25
A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers
Z7200 without oral activated charcoal, Symbicort Turbohaler without oral activated charcoal, Z7200 with oral activated charcoal - Asthma
Phase 1CompletedZambon SpA902014-09-012022-02-23
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus
Salmeterol/fluticasone Easyhaler, Salmeterol/fluticasone Easyhaler with charcoal, Seretide Diskus - Asthma
Phase 1CompletedOrion Corporation, Orion Pharma1292014-06-012015-09-29
Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.
Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend), Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend) - Asthma
Phase 1CompletedGlaxoSmithKline602013-10-212018-06-19
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus
Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal - Asthma
Phase 1CompletedOrion Corporation, Orion Pharma482013-05-012014-01-03
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus
Seretide Diskus and charcoal, Seretide Diskus, SF Easyhaler and charcoal - Asthma
Phase 1CompletedOrion Corporation, Orion Pharma502013-01-012014-01-03

Showing 20 of 28. Sign in to see all of them.

Conditions studied

Asthma (10)  ·  Anthrax (4)  ·  Pulmonary Disease, Chronic Obstructive (4)  ·  Poisoning (2)  ·  Depressive Disorder, Major (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Hypersensitivity (1)  ·  Sleep Initiation and Maintenance Disorders (1)

Sponsors

Orion Corporation, Orion Pharma (11)  ·  Centre Hospitalier Universitaire de Saint Etienne (2)  ·  Eli Lilly and Company (2)  ·  GlaxoSmithKline (2)  ·  Zambon SpA (2)  ·  AstraZeneca (1)  ·  Bristol-Myers Squibb (1)  ·  DynPort Vaccine Company LLC, A GDIT Company (1)  ·  Hoffmann-La Roche (1)  ·  PharmAthene, Inc. (1)  ·  Sanofi (1)  ·  Sunovion Respiratory Development Inc. (1)  ·  Unither Pharmaceuticals, France (1)  ·  Viatris Innovation GmbH (1)

Countries

Finland (10)  ·  United States (6)  ·  United Kingdom (5)  ·  France (4)  ·  Australia (1)  ·  Germany (1)  ·  Turkey (Türkiye) (1)

Top investigators

Leena Mattila, MD, PhD (3)  ·  Iissa Kivisto (1)  ·  Irja Korpela, MSc (1)  ·  Jeffrey Wald, MD (1)  ·  Kimmo Ingman, MD, PhD (1)

Results publications

PMID 21079762, PMID 27910037, PMID 30055824, PMID 31253162, PMID 38926266, PMID 41677208

NIH funding

2015 (2), 2019 (2), 2014 (1), 2017 (1)